达格列净治疗慢性心力衰竭的安全性研究进展

李来 龙1, 李淑 钰2, 纪征 2（

摘要

摘要:达格列净近年来成为治疗慢性心力衰竭的一线用药。因适应症的范围扩大，其使用频率越来越高，随之而来的是不良反应的报道增加，其使用中的安全性问题更应被关注，现围绕达格列净所可能引发的如泌尿生殖系感染、低血糖、酮症、体重减轻及血容量降低、直立性低血压、肾损伤等安全性问题进行综述，希望为临床更合理、安全的用药提供参考。

关键词

关键词:达格列净；钠-葡萄糖共转运蛋白2抑制剂；慢性心力衰竭；安全性

参考

[1]中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告 2022 概要.中国循环杂志,2023,38(6):583-612. DOI:10.3969/j.issn.1000-3614.2023.06.001.[2]Vaduganathan M, Cunningham JW, Claggett BL, et al. Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction: the PARAGONHF trial[J]. J Am Coll Cardiol Heart Fail, 2021, 9(5): 374-382.[3]LamprosP,PrabhjotG,AndreasPK.Epidemiology of Heart Failure[M]//Kalogeropoulos AP,SkopickiHA,ButlerJ,etal.HeartFailure:AnEssentialClinicalGuide.1sted.Boca Raton:CRC Press,2022:244-253.[4]CHENJ,NORMANDSL,WANGY,etal.National and regional trends in heart failure hospitalization and mortali-ty rates for Medica-re beneficiaries,1998-2008[J].JA-MA,2011,306(15) :1669-1678.[5]WangH,ChaiK,DuM,etal.PrevalenceandInci-denceofHeartFailureAmongUrbanPatientsinChi-na:A NationalPopulation-Based An-alysis[J].CircHeartFail,2021,14(10):e008406.[6]McDonaghTA,MetraM,AdamoM,etal.2023Fo-cusedUpdateofthe2021ESCGuidelinesforthedi-agnosisandtreatmentofacuteandchronicheartfail-ure[J].EurHeartJ,2023,44(37):3627-3639.[7]Norton L,Shannon CE,Fourcaudot M,etal.Sodium-glucose co-transporter(SGLT)and glucose transporter(GLUT)expression in the kidney of type 2 diabetic subjects[J].Diabetes Obes Metab,2017,19(9):1322-1326.[8]VAN DEN HEUVELLP,ASSINKK,MONNENSL,et al.Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter(SGLT2)[J].Hum Genet,2002,111(6):544-547.[9]Diaz-Rodriguez E,Agra RM,Ferndndez AL,et al.Effects of dapagliflozin on human epicardial adiposetissue:modulation of insulin resistance,inflammatory chemokine production,and dfferentiation abilityLJJ.Cardiovasc Res,2018,114(2):336-346.[10]Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014 Mar;103(3):373-81.[11]Fitchett D.A safety update on sodium glucose co-transporter 2 in- hibitors[J].Diabetes Obes Metab,2019,21 ( Suppl 2 ) : 34-42.DOI: 10.1111/dom.13611.[12]Dave CV,Schneeweiss S,Patorno E.Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors [J]. Diabetes Obes Metab,2019,21( 2) : 434-438. DOI: 10.1111/dom.13531.[13]Garcia-ropero A,Badimon JJ,Santos-gallego CG. The pharmacoki- netics and pharmacodynamics of SGLT2 inhibitors for type 2 diabe- tes mellitus: the latest developments[J].Expert Opin Drug Metab Toxicol,2018,14(12):1287-1302.DOI:10.1080 /17425255.2018.1551877.[14]Wang Q, Wu K,Luo X,et al.Dapagliflozin-associated euglycemic diabetic ketoacidosis presenting with severe abdominalpainmimickingacuteperitonitis[J].Cureus,2022, 14(2):e22229.[15]Zhang M, Zhang L, Wu B, et al.Dapagliflozin treatment for type 2 diabetes:a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204–221.[16]Matthews VB,Elliot RH,Rudnicka C,et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens,2017,35:2059-2068.[17]De Jong MA, Petrykiv SI, Laverman GD, et al. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis[J]. Clin J Am Soc Nephrol. 2019;14(1):66-73.[18]Jackson K, Moseley KF. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits[J]. Curr Osteoporos Rep. 2020;18(5):439-448.